Expired50% confidenceFactExact time
The senolytic drug combination dasatinib + quercetin (D+Q) has entered multiple clinical trials targeting neurodegenerative diseases, aimed at selectively eliminating senescent astrocytes and microglia in the brain.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
7/6/2026
First Seen
Valid until: 10/4/2026(expired)
Sources
Can a Nasal Spray Reverse Brain Aging? A Deep Dive into the Latest Neuroscience Breakthrough
hackernewshackernews7/4/2026
Cite This Claim
Stable URI
https://kongchang.com/claim/115796API
curl https://kongchang.com/api/v1/knowledge/claims/115796MCP
get_claim(id=115796)